General

How do I qualify for the FDA small business user fee reduction?

For a small medical device company aiming to qualify for the FDA’s Small Business Determination (SBD) program to reduce premarket submission user fees, what are the critical steps and common pitfalls involved in preparing a successful application? Specifically, when calculating the "gross receipts or sales" to meet the required revenue threshold, how should a company account for non-sales income like research grants, milestone payments, or investment funding? Furthermore, how does the FDA's definition of an "affiliate" impact the calculation, particularly in complex scenarios involving parent companies, sister entities, or significant investors, and what level of documentation is needed to demonstrate control or lack thereof? Regarding process and timing, must SBD qualification be officially granted *before* a 510(k) or other marketing application is submitted to ensure the reduced fee is accepted, and what are the risks if the SBD application is still pending when the submission fee is due? For companies based outside the United States that do not file U.S. federal tax returns, what alternative financial documentation is typically required to verify their global revenue, and what are the best practices for presenting this information clearly to the FDA? Finally, once SBD status is approved for a given fiscal year, what is the precise scope of its application—does it automatically apply to all subsequent user-fee-incurring submissions filed by that company within that year, or are there limitations to consider? --- *This Q&A was AI-assisted and reviewed for accuracy by Lo H. Khamis.*
💬 1 answers 👁️ 21 views 👍 0
Asked by Lo H. Khamis

Answers

👍 5
# How to Qualify for the FDA Small Business User Fee Reduction For small and emerging medical device companies, navigating the U.S. regulatory landscape involves significant investment, and FDA user fees for premarket submissions can represent a substantial cost. To support innovation and reduce the financial burden on smaller entities, the FDA offers the Small Business Determination (SBD) program, which provides a significant reduction in user fees for applications like 510(k)s, De Novo requests, and Premarket Applications (PMAs). Qualifying for this program, however, requires a meticulous and timely application process. Companies must provide detailed financial documentation that accurately reflects their "gross receipts or sales" and accounts for all affiliated businesses. A misunderstanding of the FDA’s definitions for revenue or affiliates can lead to a rejected application, forcing the company to pay the full standard user fee and potentially delaying its submission timeline. This article provides a detailed guide on the critical steps, common pitfalls, and strategic considerations for preparing a successful SBD application. ### Key Points * **Approval Must Precede Submission:** A company must have an officially granted Small Business Decision Number from the FDA *before* filing its marketing application to be eligible for the reduced fee. Submitting with a pending SBD application requires payment of the full standard fee. * **"Gross Receipts or Sales" is All-Encompassing:** This calculation is not limited to product sales. It generally includes all revenue from all sources, such as research grants, milestone payments, and other business income, before deducting returns and allowances. * **Affiliate Revenue Must Be Consolidated:** The total gross receipts calculation must include the revenue of the applicant company plus all of its domestic and foreign affiliates, including parent companies, subsidiaries, and any other entity under common control. * **Documentation is Non-Negotiable:** U.S. firms must typically provide their complete, signed federal income tax return. Foreign firms must submit equivalent official documentation, such as a government-certified tax return or an audited financial statement, along with a certified English translation. * **SBD Status is Annual:** Approval is granted for a specific federal fiscal year (October 1 to September 30). A company must reapply each year it wishes to claim small business status. * **Official FDA Resources are Primary:** Revenue thresholds, application forms (Form FDA 3602), and specific requirements are updated periodically. Sponsors must always consult the official FDA website for the most current information. ## Understanding the Small Business Determination (SBD) Program The SBD program is administered by the Center for Devices and Radiological Health (CDRH) under the authority of the Medical Device User Fee Amendments (MDUFA). Its sole purpose is to determine eligibility for reduced user fees for certain premarket submissions. To qualify, a company, along with all of its affiliates, must have gross receipts or sales of no more than a specific revenue threshold for its most recent tax year. This threshold is subject to change, so it is critical to verify the current amount on the FDA's website. If a company meets this criterion and submits a complete application, the FDA will issue a Small Business Decision Number that is valid for the remainder of the federal fiscal year. ## Step-by-Step: Preparing a Successful SBD Application A successful SBD application hinges on careful preparation and a thorough understanding of FDA’s requirements. Missing a step or misinterpreting a definition is a common reason for rejection. ### Step 1: Confirm the Current Eligibility Threshold Before beginning any paperwork, visit the FDA's website to confirm the current revenue cap for small business qualification. This figure is the benchmark against which all financial calculations will be measured. ### Step 2: Calculate Total "Gross Receipts or Sales" This is one of the most critical and often misunderstood aspects of the application. The FDA’s definition of "gross receipts or sales" is intentionally broad. * **What to Include:** The calculation should encompass all income generated by the business. This typically includes: * Revenue from product sales. * Income from services. * Research and development grants (e.g., from NIH, BARDA). * Milestone payments from partnership or licensing agreements. * Interest and investment income. * **What to Exclude:** Generally, the only amounts that can be deducted are returns and allowances. Capital infusions from investors (i.e., selling equity) are typically not counted as revenue, but any interest or income generated from that capital is. * **Common Pitfall:** A common mistake is for a pre-revenue company to assume its gross receipts are zero. If the company received a $1 million research grant in its last tax year, that $1 million is typically considered part of its gross receipts for the SBD calculation. ### Step 3: Identify All Affiliates The FDA requires the consolidation of financials from the applicant company and all its affiliates. An "affiliate" is any business entity that controls, is controlled by, or is under common control with the applicant. * **Defining Control:** Control is typically defined as owning 50% or more of the voting stock or having the power to direct the management and policies of the business. * **Common Affiliate Scenarios:** * **Parent Company:** If Company A owns 75% of your company, Company A is an affiliate. Its total global revenue must be added to yours. * **Subsidiary:** If your company owns 60% of Company B, Company B is an affiliate. Its revenue must be included. * **Sister Company:** If Parent Company C owns both your company and Company D, then Company D is a sister company and an affiliate. Its revenue must also be included. * **Complex Scenarios (e.g., Venture Capital):** If a single venture capital firm or investor owns more than 50% of your company, that firm and potentially its other portfolio companies could be considered affiliates. This area can be complex, and the documentation must clearly demonstrate the control structure. If no single entity has control, this should be clearly explained. * **Common Pitfall:** Failing to identify and include the revenue of a foreign parent company is a frequent cause for application rejection. The calculation must be global. ### Step 4: Gather and Prepare Required Documentation The required documentation depends on whether the company is based in the United States. * **For U.S.-Based Companies:** The primary document is the most recent federal income tax return. You must submit the *entire, signed* return, not just the first page. The FDA uses this to verify the gross receipts or sales reported on the SBD application form. * **For Foreign Companies:** Since foreign companies do not file U.S. federal tax returns, they must provide equivalent documentation to verify their total global revenue. Acceptable documents often include: * **An official tax document from the national taxing authority:** This is the preferred document. It should clearly show the company’s total income for the most recent tax year. * **An independently audited financial statement:** This should be prepared by a licensed, independent public accountant and must clearly state the company's total gross receipts or sales. * **Critical Requirements for Foreign Documentation:** 1. **English Translation:** All documents must be provided in English. If the original is in another language, a certified translation must be attached. 2. **Currency Conversion:** All financial figures must be converted to U.S. dollars, and the exchange rate used must be specified. It is best practice to use the average exchange rate for the period covered by the financial document. ## Strategic Considerations and Application Timing Timing is a crucial strategic element of the SBD process. Mismanaging the timeline can negate the entire benefit of the program. **SBD Approval Must Be Secured *Before* You Submit** A company is only eligible for the reduced user fee if it has an approved SBD number *at the time it files its marketing application*. The SBD number must be prominently included in the submission cover letter. **The Risk of a Pending SBD Application** If a marketing application is submitted while the SBD application is still under review by the FDA, the company is required to pay the **full standard user fee**. If the SBD application is subsequently approved, the company may request a refund for the difference. However, this process can be lengthy, and a refund is not guaranteed if there were issues with either submission. This creates unnecessary financial uncertainty and administrative burden. **Recommended Timeline** To avoid this risk, sponsors should apply for SBD status well in advance of a planned marketing submission. A conservative recommendation is to submit the SBD application **at least 60 days before** the target date for the marketing submission. The FDA’s review goal for SBD applications is 60 calendar days, but it is wise to allow for potential requests for additional information. ## Scope and Duration of SBD Approval Once approved, an SBD designation is valid for the U.S. government’s fiscal year, which runs from **October 1 to September 30**. This means a single SBD approval number can be used for all qualifying user-fee-incurring submissions filed by that company (and its listed affiliates) within that fiscal year. For example, if a company receives SBD approval in November 2023, that status is valid until September 30, 2024. The company must reapply for the next fiscal year (FY2025) if it plans to file another submission on or after October 1, 2024. ### Key FDA References When preparing an SBD application, sponsors should always refer directly to the FDA's website for the latest forms, revenue thresholds, and guidance. Generic references that provide context for this process include: * FDA's guidance and information on the Medical Device User Fee Amendments (MDUFA). * The official FDA webpage for the Small Business Determination (SBD) Program. * General regulations for premarket submissions under 21 CFR, such as 21 CFR Part 807 for 510(k) procedures. For current FDA user fee information, sponsors should consult the FDA website at https://www.fda.gov/industry/fda-user-fees. ### How tools like Cruxi can help Managing the documentation for both an SBD application and a major marketing submission requires meticulous organization. Tools like Cruxi can help teams centralize regulatory documents, track deadlines, and build a structured submission file, ensuring that critical information, such as an SBD approval number, is correctly included in the final package. *** *This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.* --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*